Document is current
Any future updates will be listed below
-
Authors
Christensen, Michael Cronquist http://orcid.org/0000-0002-3605-7223
Ren, Hongye http://orcid.org/0000-0003-0080-4765
Fagiolini, Andrea http://orcid.org/0000-0001-5827-0853
- License Information
-
More Information
Article History
Received: 16 February 2022
Accepted: 22 March 2022
First Online: 4 April 2022
Declarations
:
: All participants (patients and healthcare providers) had previously accepted the online panel partners’ privacy policies and terms and conditions, including consent to participate in future research. Informed consent was also obtained from all participants specifically for this study prior to screening. The study and all associated materials were approved by an institutional review board prior to initiation (Veritas IRB, Montreal, QC, Canada). The study was conducted in accordance with the European Pharmaceutical Market Research Association (EphMRA) code of conduct, which ensures respondent confidentiality, and adhered to General Data Protection Regulations (GDPR) and all local market laws regarding data protection.
: Not applicable.
: MCC is an employee of H. Lundbeck A/S. HR was an employee of H. Lundbeck A/S at the time this study was conducted. AF has been a consultant and/or speaker and/or has received research grants from Allergan, Angelini, Aspen, Boehringer Ingelheim, Daiichi Sankyo Brasil Farmacêutica, DOC Generici, FB-Health, Italfarmaco, Janssen, Lundbeck, Mylan, Otsuka, Pfizer, Recordati, Sanofi Aventis, Sunovion, and Vifor Pharma.
